In an 83‑year‑old male with stage 3a chronic kidney disease, systolic heart failure, pre‑diabetes, and current therapy including torsemide, is it reasonable to add empagliflozin (Jardiance) to his regimen, and should any medication adjustments be made?

Adding Jardiance (Empagliflozin) to This Patient's Regimen

Direct Recommendation

Yes, you should add empagliflozin 10 mg daily to this patient's regimen, and you should consider reducing his torsemide dose by approximately 50% within the first 2-4 weeks after initiation while monitoring for volume depletion. 1

---

Rationale for Adding Empagliflozin

Strong Indications Present

This 83-year-old patient has multiple compelling indications for SGLT2 inhibitor therapy:

• Acute-on-chronic systolic heart failure: The 2022 ACC/AHA/HFSA guidelines and 2021 ESC/HFA guidelines recommend SGLT2 inhibitors as core therapy for all patients with HFrEF, regardless of diabetes status 2, 3
• Stage 3a CKD (eGFR 43-50 mL/min/1.73 m²): The 2022 ADA/KDIGO consensus and KDIGO 2020 guidelines recommend SGLT2 inhibitors for patients with eGFR ≥20 mL/min/1.73 m² 1, 4
• Pre-diabetes (glucose 148 mg/dL, prior A1C 6.1%): SGLT2 inhibitors provide cardiovascular and renal benefits independent of glucose-lowering effects 1

Evidence Supporting Use in This Patient Population

• Empagliflozin is specifically proven effective in patients with eGFR ≥20 mL/min/1.73 m² based on the EMPEROR-Reduced and EMPA-KIDNEY trials 1, 5
• Benefits are maintained in elderly patients: The EMPEROR-Reduced trial demonstrated effectiveness in vulnerable populations including the elderly, with a favorable safety profile 3, 6
• Works across the spectrum of kidney function: In EMPA-KIDNEY, empagliflozin reduced kidney disease progression by 28% (HR 0.72) in patients with eGFR as low as 20 mL/min/1.73 m² 5, 7
• Benefits occur regardless of albuminuria status: Even without significant albuminuria data in this patient, empagliflozin slows eGFR decline across all albuminuria levels 8, 5

---

Medication Adjustments Required

1. Diuretic Dose Reduction (CRITICAL)

Reduce torsemide from 10 mg to 5 mg daily within 2-4 weeks of starting empagliflozin 1:

• The ADA/KDIGO guidelines specifically recommend "proactive dose reduction of diuretics in patients at high risk" when initiating SGLT2 inhibitors 1
• This patient is at high risk for volume depletion due to: age 83 years, baseline eGFR 43-50 mL/min/1.73 m², and current loop diuretic use 9
• The EMPEROR-Reduced trial showed empagliflozin reduced the need for diuretic intensification, even in patients with congestion 3
• Monitor for orthostatic hypotension, dizziness, and acute changes in creatinine during the first month 9

2. No Insulin/Sulfonylurea Adjustment Needed

• This patient is not on insulin or sulfonylureas, so no hypoglycemia risk mitigation is required 1
• His pre-diabetes status (glucose 148 mg/dL, A1C 6.1%) poses minimal hypoglycemia risk 1

3. Continue Current Cardiac Medications

• Do NOT adjust lisinopril 2.5 mg, carvedilol 12.5 mg BID, or amiodarone 200 mg 1
• SGLT2 inhibitors are unique in that they do not affect blood pressure, heart rate, or potassium levels, and require no dose adjustment or up-titration 3
• The effectiveness of empagliflozin is maintained regardless of background HF medication doses 3

---

Monitoring Plan

First 2-4 Weeks After Initiation

• Assess volume status weekly: Check for orthostatic hypotension, dizziness, or symptoms of dehydration 9
• Recheck basic metabolic panel at 1 month: Expect a transient 2-3 mL/min/1.73 m² eGFR dip (approximately 6% decline) in the first 2 months, which is reversible and does not require drug discontinuation 1, 8
• Monitor for genital mycotic infections: Counsel on genital hygiene; risk is 6% vs. 1% with placebo 1, 9

Ongoing Monitoring

• Continue empagliflozin even if eGFR falls below 20 mL/min/1.73 m² unless the patient is not tolerating treatment or requires kidney replacement therapy 1
• Recheck eGFR and electrolytes every 3 months as planned 4
• Monitor potassium levels: Empagliflozin may facilitate continuation of other medications (e.g., lisinopril) by reducing hyperkalemia risk 3

---

Critical Safety Considerations

Hold Empagliflozin During Acute Illness

• Discontinue temporarily during COPD exacerbations, infections, or surgery to prevent euglycemic ketoacidosis 1, 9
• This patient is currently being treated for a COPD exacerbation with antibiotics and steroids; wait until the acute exacerbation resolves before starting empagliflozin 9
• Consider holding empagliflozin at least 3 days before his upcoming surgery (abdominal aneurysm leak repair) 9

Educate on Ketoacidosis Warning Signs

• Instruct the patient to discontinue empagliflozin and seek immediate medical attention if he develops nausea, vomiting, abdominal pain, generalized malaise, or shortness of breath 9
• Euglycemic ketoacidosis can occur with blood glucose <250 mg/dL 9
• Risk factors in this patient include: reduced caloric intake (due to respiratory symptoms), acute illness (COPD exacerbation, UTI), and upcoming surgery 9

Urinary Tract Infection Risk

• Monitor for recurrent UTIs: This patient recently had a UTI treated with antibiotics 9
• SGLT2 inhibitors increase the risk of urinary tract infections, including urosepsis and pyelonephritis 9
• Treat UTIs promptly if they recur 9

---

Expected Benefits in This Patient

Cardiovascular Outcomes

• 25% reduction in cardiovascular death or HF hospitalization (HR 0.72-0.78) 2, 7
• 30% reduction in HF hospitalization alone 2, 7
• Benefits occur within weeks of initiation, independent of age, sex, or background medical therapy 3

Renal Outcomes

• 50% reduction in the rate of chronic eGFR decline (1.37 mL/min/1.73 m² per year slower decline) 1, 8
• 28% reduction in kidney disease progression (HR 0.72) 5
• Long-term kidney protection despite initial transient eGFR dip 1, 8

Additional Benefits

• Reduced need for diuretic intensification 3
• Potential weight loss (patient's BMI is 35.0) 10
• Improved dyspnea and NT-proBNP levels in elderly patients with acute HF 6

---

Common Pitfalls to Avoid

1. Do NOT wait for diabetes diagnosis: Empagliflozin benefits are independent of diabetes status 1, 2
2. Do NOT discontinue empagliflozin if eGFR falls below initiation threshold: Continue therapy unless the patient is not tolerating treatment or requires dialysis 1
3. Do NOT start empagliflozin during acute illness: Wait until the COPD exacerbation and UTI resolve 9
4. Do NOT forget to reduce diuretics proactively: This patient is at high risk for volume depletion 1, 9
5. Do NOT overlook genital hygiene counseling: Genital mycotic infections occur in 6% of patients 1, 9

---

Timing of Initiation

Start empagliflozin 10 mg daily after:

• COPD exacerbation resolves (currently on antibiotics and steroids) 9
• UTI symptoms fully resolve 9
• Volume status is reassessed and stable 9

Hold empagliflozin at least 3 days before his upcoming vascular surgery and restart only after he is eating normally and risk factors for ketoacidosis are resolved 9